ANN ARBOR, Mich.--(BUSINESS WIRE)--
Esperion Therapeutics, Inc. (Nasdaq:ESPR), a clinical-stage
biopharmaceutical company focused on developing and commercializing
first-in-class, oral, low-density lipoprotein cholesterol (LDL-C)
lowering therapies for the treatment of hypercholesterolemia, today
announced that it will host its inaugural analyst and investor day event
and webcast for institutional investors and research analysts on
Tuesday, July 29 at 8:30 a.m. Eastern Time.
The event can be accessed by dialing (877) 831-3840 (domestic) or (253)
237-1184 (international) five minutes prior to the start of the event
and providing access code 76041931. A live, listen-only webcast of the
event can be accessed on the investor relations section of the Esperion
website at www.esperion.com.
A webcast replay will be available approximately two hours after
completion of the event and will be archived on the Company's website.
Esperion's Commitment to Cardiometabolic Disease
Esperion is committed to improving the lives of patients with
cardiometabolic diseases. The Esperion team leverages its understanding
of and experience with key biological pathways to discover or license
and develop innovative therapies for the treatment of patients with
unmet needs, especially those patients with hypercholesterolemia who
have uncontrolled cholesterol levels despite the use of currently
available therapies. Esperion has assembled a portfolio of programs
including one product candidate in late-stage clinical evaluation and
two pre-clinical product candidates.
About Esperion Therapeutics
Esperion Therapeutics, Inc. is a clinical stage biopharmaceutical
company focused on developing and commercializing first-in-class, oral,
LDL-cholesterol lowering therapies for the treatment of patients with
hypercholesterolemia and other cardiometabolic risk markers. ETC-1002,
Esperion's lead product candidate, is a unique, first-in-class, orally
available, once-daily small molecule designed to lower LDL-cholesterol
levels and avoid the side effects associated with therapies currently
available for lowering LDL-cholesterol. ETC-1002 is being developed
primarily for patients intolerant to statins and with elevated levels of
LDL-cholesterol. Phase 2b clinical trials for ETC-1002 are currently
underway and build upon the successful and comprehensive Phase 1 and
Phase 2a programs. For more information, please visit www.esperion.com
and follow us on Twitter at https://twitter.com/EsperionInc.
Source: Esperion Therapeutics, Inc.